title: [Tumor lysis syndrome after FOLFIRI+cetuximab for ascending colon cancer].
abstract: We report a case of an 83-year-old woman who developed tumor lysis syndrome (TLS) 5 days after FOLFIRI+cetuximab (Cmab) therapy. A huge ascending colon cancer measuring 10 cm in diameter and with peritoneal dissemination was diagnosed. Following successful therapy with FOLFIRI alone, FOLFIRI+Cmab was administered. On day 5, TLS was diagnosed with hyperuricemia, hyperkalemia, hyperphosphatemia, and an increase in serum creatinine. Intravenous furosemide, volume loading, and glucose-insulin therapy resulted in improvement of laboratory data in 2 days. However, she died on the 34th day due to multiple organ failure caused by aspiration pneumonia following small intestine functional ileus. Although TLS is a rare complication in colon cancer, its onset must be taken into consideration. Also, risk assessment and preventive therapy for TLS should be performed before cancer treatment.
authors.affiliation: Department of Surgery, Shimada Hospital.
authors.forename: Satoru
authors.initials: S
authors.lastname: Matsuyama
authors.forename: Takako
authors.initials: T
authors.lastname: Kuramoto
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Tanaka
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Hashiguchi
mesh_terms: D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068818:Cetuximab / Q000008:administration & dosage* / Q000009:adverse effects; D044682:Colon, Ascending; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D015275:Tumor Lysis Syndrome / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin